DK2854850T3 - Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom - Google Patents

Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom Download PDF

Info

Publication number
DK2854850T3
DK2854850T3 DK13793069.9T DK13793069T DK2854850T3 DK 2854850 T3 DK2854850 T3 DK 2854850T3 DK 13793069 T DK13793069 T DK 13793069T DK 2854850 T3 DK2854850 T3 DK 2854850T3
Authority
DK
Denmark
Prior art keywords
syndrome
prevention
compositions
treatment
radiation disease
Prior art date
Application number
DK13793069.9T
Other languages
English (en)
Inventor
Richard Kolesnick
Jimmy Rotolo
Original Assignee
Sloan Kettering Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer Res filed Critical Sloan Kettering Inst Cancer Res
Application granted granted Critical
Publication of DK2854850T3 publication Critical patent/DK2854850T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK13793069.9T 2012-05-25 2013-05-28 Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom DK2854850T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261651729P 2012-05-25 2012-05-25
PCT/US2013/042941 WO2013177596A2 (en) 2012-05-25 2013-05-28 Methods for treating gi syndrome and graft versus host disease

Publications (1)

Publication Number Publication Date
DK2854850T3 true DK2854850T3 (da) 2021-08-30

Family

ID=49624550

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13793069.9T DK2854850T3 (da) 2012-05-25 2013-05-28 Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom

Country Status (8)

Country Link
US (2) US10722577B2 (da)
EP (2) EP3903820B1 (da)
JP (4) JP6257600B2 (da)
AU (1) AU2013266069B2 (da)
CA (2) CA3172599C (da)
DK (1) DK2854850T3 (da)
ES (1) ES2879931T3 (da)
WO (1) WO2013177596A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
KR102617655B1 (ko) 2012-11-23 2023-12-27 세레스 테라퓨틱스, 인코포레이티드 상승작용적 박테리아 조성물, 그리고 이의 제조 방법 및 용도
AU2014212003C1 (en) 2013-02-04 2020-07-16 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
KR102452866B1 (ko) 2013-10-25 2022-10-07 파마싸이클릭스 엘엘씨 이식편 대 숙주 질환의 치료 및 예방 방법
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
TW202402295A (zh) * 2013-12-02 2024-01-16 美商製藥公司 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
AU2015300902B2 (en) 2014-08-07 2020-05-28 Ceramide Therapeutics Anti-ceramide antibodies
WO2016086161A1 (en) * 2014-11-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Intestinal microbiota and gvhd
EP3328429B1 (en) 2015-07-31 2025-07-16 The Research Institute at Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
US20180346571A1 (en) * 2015-11-17 2018-12-06 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
WO2018129092A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
US11564982B2 (en) 2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
CA3080586A1 (en) 2017-10-30 2019-05-09 Seres Therapeutics, Inc. Compositions and methods for treating antibiotic resistance
BR112021003156A2 (pt) 2018-08-23 2021-05-11 Seagen, Inc. composição, anticorpo que se liga ao tigit humano, formulação farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, métodos para a produção de um anticorpo que se liga ao tigit humano e de anticorpos afucosilados que se ligam a tigit e para o tratamento de um câncer, e, kit.
BR112021006321A2 (pt) 2018-10-05 2021-07-06 Res Inst Nationwide Childrens Hospital derivados de proteína hmgb1 para remoção de biofilmes
US20220023419A1 (en) * 2018-11-28 2022-01-27 The Council Of The Queensland Institute Of Medical Research Inhibiting inflammation
CN110237075A (zh) * 2019-06-25 2019-09-17 华中农业大学 一种达氟沙星在治疗副猪嗜血杆菌药物中的用途
CN114401986B (zh) 2019-07-08 2024-11-08 国家儿童医院研究所 破坏生物膜的抗体组合物
JP2023533504A (ja) * 2020-07-07 2023-08-03 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルムの処置および予防のための併用療法
CA3212333A1 (en) * 2021-03-16 2022-09-22 Richard Kolesnick Wound healing enhancement with anti-ceramide antibodies
KR20250156322A (ko) * 2024-04-25 2025-11-03 한국 한의학 연구원 트로바플록사신을 유효성분으로 함유하는 항암제 내성암의 예방 또는 치료용 약학 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
JPH02128697A (ja) 1988-11-09 1990-05-17 Hoechst Japan Ltd 抗フコシルセラミドモノクローナル抗体
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
WO1998019167A2 (en) 1996-10-29 1998-05-07 Fred Hutchinson Cancer Research Center, Inc. Cell stress regulated human mhc class i gene
CA2399080C (en) * 2000-02-03 2013-05-21 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
AU2002211681A1 (en) 2000-10-12 2002-04-22 Curagen Corporation Proteins and nucleic acids encoding same
US20040109855A1 (en) * 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
CA2531878A1 (en) 2003-05-09 2005-03-24 Curagen Corporation Therapeutic use of g53135-05(fgf-20) in radiation protection
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
KR100565437B1 (ko) 2003-07-31 2006-03-30 중앙대학교 산학협력단 신규한 스핑고마이엘리나제 효소, 그에 대한 항체, 안티센스 및 제조방법
EP1904101A4 (en) 2005-06-08 2011-06-15 Univ Duke ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION
WO2007095594A2 (en) * 2006-02-14 2007-08-23 Cellerant Therapeutics, Inc. Methods and compositions for enhancing engraftment of hematopoietic stem cells
JP5924863B2 (ja) * 2007-05-06 2016-05-25 スローン ケタリング インスティテュート フォア キャンサー リサーチ Ｇｉ症候群及び移植片対宿主病を治療及び予防する方法
KR20110092351A (ko) * 2008-12-08 2011-08-17 솔리제닉스, 인크. 방사선 및 화학요법 손상에서 사용되는 국소적 활성 스테로이드

Also Published As

Publication number Publication date
JP2019142903A (ja) 2019-08-29
EP2854850A2 (en) 2015-04-08
WO2013177596A2 (en) 2013-11-28
US20220118087A1 (en) 2022-04-21
JP6761792B2 (ja) 2020-09-30
WO2013177596A3 (en) 2014-02-13
ES2879931T3 (es) 2021-11-23
CA3172599A1 (en) 2013-11-28
AU2013266069B2 (en) 2018-03-15
EP3903820A1 (en) 2021-11-03
JP2022064935A (ja) 2022-04-26
EP2854850B1 (en) 2021-05-26
JP2015523970A (ja) 2015-08-20
JP2018048158A (ja) 2018-03-29
CA2874673A1 (en) 2013-11-28
JP7072538B2 (ja) 2022-05-20
JP6257600B2 (ja) 2018-01-10
JP7371144B2 (ja) 2023-10-30
CA2874673C (en) 2022-11-22
US10722577B2 (en) 2020-07-28
US20150216971A1 (en) 2015-08-06
EP2854850A4 (en) 2016-01-06
EP3903820B1 (en) 2025-05-07
CA3172599C (en) 2025-10-07
AU2013266069A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
DK2854850T3 (da) Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom
DK2818481T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK2841097T3 (da) Sammensætninger og fremgangsmåder til behandling og forebyggelse af porcint reproduktions- og respirationssyndrom
DK2532680T3 (da) Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK3366307T3 (da) Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
DK2532366T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK2935303T3 (da) 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV
DK2804587T3 (da) Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed
DK3082831T3 (da) Sammensætning på basis af methyl-cyclodextriner til behandling og/eller forebyggelse af sygdomme ved forøgelse af koncentrationen af hdl-kolesterol
DK2981274T3 (da) Probiotiske stammer til anvendelse ved behandling eller forebyggelse af osteoporose
BR112015001838A2 (pt) composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo.
DK2819602T3 (da) Kateter til behandling af atrieflagren med enkelt-virkende dobbelt afbøjningsmekanisme
LT2916860T (lt) Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą
DK3102189T3 (da) Sammensætning og fremgangsmåde til at fremme søvn
SI3513806T1 (sl) Sestava imunogena
DK2861273T3 (da) Anvendelse af heparin og kulhydrater til behandling af cancer.
DK3238707T3 (da) Sammensætninger og fremgangsmåder til behandling af intestinal hyperpermeabilitet
DK3395353T5 (da) Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade
DK2964255T3 (da) Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI)
DK2961420T3 (da) Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom
DK2702992T3 (da) Anvendelse af melatonin til behandling af og/eller forebyggelse af mucositis
DK2791684T3 (da) Fremgangsmåder til forebyggelse eller behandling af forstyrrelser ved forøgelse af biotilgængeligheden af jern og relateret farmaceutisk formulering
HUE040496T2 (hu) Vegyületek elhízás kezelésére és alkalmazási eljárásaik
DK3175852T3 (da) Difluorlactamsammensætninger til EP4-medierede osteorelaterede sygdomme og tilstande